METHODS: We retrospectively assessed the treatment and outcomes of patients with SBP in a hospital in China from 2008 to 2021. Twenty-four patients treated over 13 years with SBP were enrolled in this retrospective study.
RESULTS: The most common sites for SBP were the axial skeleton and femur. The M protein was detected in 11 patients (46 %), of which 8 (33 %) had light chains, 2 (8 %) had immunoglobulin G kappa and 1 (4 %) had immunoglobulin D kappa. Flow cytometry revealed that 5 patients (21 %) had minimal bone marrow involvement. The treatment included chemotherapy, surgery, and radiotherapy in 18 (75 %), 12 (50 %), and 9 (38 %) patients, respectively, of whom 13 (54 %) received combined treatment. Over a median follow-up period of 67.2 months, 9 patients (38 %) developed MM in a median time of 101.5 months. The 5- and 10-year progression-free survival rates were 67.3 % and 37.4 %, respectively. One patient died due to pneumonia without progression and the other died due to relapse.
CONCLUSIONS: This study confirmed the high rate of progression of SBP to MM, indicating a need for adjunct chemotherapy for the management of SBP.
方法:我们回顾性评估了2008年至2021年中国某医院SBP患者的治疗和预后。这项回顾性研究招募了24名接受SBP治疗超过13年的患者。
结果:SBP最常见的部位是中轴骨骼和股骨。在11例(46%)患者中检测到M蛋白,其中8个(33%)有轻链,2(8%)具有免疫球蛋白Gκ,1(4%)具有免疫球蛋白Dκ。流式细胞术显示5例患者(21%)的骨髓受累很小。治疗包括化疗,手术,和放疗在18(75%),12(50%),9名(38%)患者,分别,其中13人(54%)接受综合治疗。在67.2个月的中位随访期内,9名患者(38%)在101.5个月的中位时间内发展为MM。5年和10年无进展生存率分别为67.3%和37.4%,分别。一名患者因肺炎而死亡,但没有进展,另一名患者因复发而死亡。
结论:这项研究证实了SBP进展为MM的高比率,表明需要辅助化疗来管理SBP。